相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year
Najeeda Yasmeen et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?
Emily Wright et al.
DERMATOLOGY AND THERAPY (2021)
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
Kristian Reich et al.
LANCET (2021)
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
Kenneth B Gordon et al.
LANCET (2021)
UPADACITINIB RESPONSE RATES IN PATIENTS WITH PSORIATIC ARTHRITIS ENROLLED IN THE SELECT-PSA-1 AND SELECT-PSA-2 TRIALS ASSESSED ACCORDING TO MODIFIED PSARC
Laura C. Coates et al.
RHEUMATOLOGY (2021)
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Philip J. Mease et al.
RHEUMATOLOGY (2021)
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis
Ahmed Mourad et al.
JOURNAL OF RHEUMATOLOGY (2020)
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial
Christopher T Ritchlin et al.
LANCET (2020)
GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
Elsa Vieira-Sousa et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis
April W. Armstrong et al.
JAMA DERMATOLOGY (2020)
Treatment guidelines in psoriatic arthritis
Alexis Ogdie et al.
RHEUMATOLOGY (2020)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel -group, randomised, active-controlled, phase 3b trial
Iain B. McInnes et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis
Dafna D. Gladman et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2020)
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis
S. K. Mahil et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey
William Tillett et al.
RHEUMATOLOGY AND THERAPY (2020)
Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study
P. G. Conaghan et al.
RMD OPEN (2020)
NETAKIMAB DECREASES DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED DOUBLE-BLIND PHASE 3 CLINICAL TRIAL (PATERA)
T. Korotaeva et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
EFFICACY AND SAFETY OF UPADACITINIB VERSUS PLACEBO AND ADALIMUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NON-BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-1): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
I. Mcinnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS
I. Mcinnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (SELECT-PSA-2): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL
M. C. Genovese et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
ADALIMUMAB INTRODUCTION VERSUS METHOTREXATE DOSE ESCALATION IN PATIENTS WITH INADEQUATELY CONTROLLED PSORIATIC ARTHRITIS: RESULTS FROM RANDOMIZED PHASE 4 CONTROL STUDY
L. C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis
Adeline Ruyssen-Witrand et al.
RMD OPEN (2020)
Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial
Philip J. Mease et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
Laura M. Sawyer et al.
PLOS ONE (2019)
Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2019)
SECUKINUMAB IMPROVES AXIAL MANIFESTATIONS IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO NSAIDS: PRIMARY ANALYSIS OF THE MAXIMISE TRIAL
Xenofon Baraliakos et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2019)
A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis
Jawad Bilal et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2018)
Efficacy and safety of biologics targeting interleukin-6,-12/23 and-17 pathways for peripheral psoriatic arthritis: a network meta-analysis
Dongze Wu et al.
RHEUMATOLOGY (2018)
Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis
G. G. Song et al.
ZEITSCHRIFT FUR RHEUMATOLOGIE (2018)
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Atul Deodhar et al.
LANCET (2018)
Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
Philip J. Mease et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis
Iain B. McInnes et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease et al.
LANCET (2018)
Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity
Laura C. Coates et al.
BMC RHEUMATOLOGY (2018)
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)
Peter Nash et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effects of antenatal diet and physical activity on maternal and fetal outcomes: individual patient data meta-analysis and health economic evaluation
Ewelina Rogozinska et al.
HEALTH TECHNOLOGY ASSESSMENT (2017)
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
Peter Nash et al.
LANCET (2017)
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
P. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
Dafna Gladman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis Results Through Week Twenty-Four of the GO-VIBRANT Study
Arthur Kavanaugh et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J. Edwards et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2016)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Epidemiology of Psoriatic Arthritis
Alexis Ogdie et al.
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA (2015)
Psoriatic arthritis: latest treatments and their place in therapy
Eun Jin Kang et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2015)
Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis
Muhammad Haroon et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double- blind randomised placebo- controlled study (RAPID-PsA)
P. J. Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Evidence Synthesis for Decision Making 2: A Generalized Linear Modeling Framework for Pairwise and Network Meta-analysis of Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 3: HeterogeneitySubgroups, Meta-Regression, Bias, and Bias-Adjustment
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Evidence Synthesis for Decision Making 4: Inconsistency in Networks of Evidence Based on Randomized Controlled Trials
Sofia Dias et al.
MEDICAL DECISION MAKING (2013)
Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
Asta Baranauskaite et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study
Georg Schett et al.
ARTHRITIS AND RHEUMATISM (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial
Wolfram Sterry et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Golimumab, a New Human Tumor Necrosis Factor α Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study
Arthur Kavanaugh et al.
ARTHRITIS AND RHEUMATISM (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
Established Psoriatic Arthritis: Clinical Aspects
Philip S. Helliwell
JOURNAL OF RHEUMATOLOGY (2009)
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis - Results of a double-blind, randomized, placebo-controlled trial
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2005)
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Etanercept treatment of psoriatic arthritis - Safety, efficacy, and effect on disease progression
PJ Mease et al.
ARTHRITIS AND RHEUMATISM (2004)
分享论文
